



Clinical outcomes and quantitative CT analysis after bronchoscopic lung volume reduction using valves for advanced emphysema

Fangfang Guo¹, Junfang Huang¹, Yan Hu¹, Jianxing Qiu², Hong Zhang¹, Wei Zhang¹, Yuan Cheng¹, Jiping Liao¹, Guangfa Wang¹

¹Department of Pulmonary and Critical Care Medicine, Peking University First Hospital, Beijing, China; ²Department of Radiology, Peking University First Hospital, Beijing, China

Contributions: (I) Conception and design: F Guo, J Huang, Y Hu, G Wang; (II) Administrative support: F Guo, G Wang; (III) Provision of study materials or patients: Y Hu, J Qiu, H Zhang, W Zhang, Y Cheng, J Liao, G Wang; (IV) Collection and assembly of data: F Guo, J Huang, Y Hu; (V) Data analysis and interpretation: F Guo, J Huang, Y Hu, G Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Guangfa Wang, MD. Department of Pulmonary and Critical Care Medicine, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing 100034, China. Email: wangguangfa@hotmail.com.

Background: Bronchoscopic lung volume reduction (BLVR) using Zephyr endobronchial valve (EBV) and intrabronchial valve (IBV) has been shown to improve lung function and exercise capacity in severe emphysema. However, changes in airway structures and whether these are related to the clinical improvements remain unclear.

Methods: A retrospective study was performed on patients treated with BLVR. We compared changes in 2nd-, 3rd-, and 4th-generation bronchial structures after therapy, including wall thickness (WT), percentage of wall thickness (WT%), intraluminal area (LA), wall area (WA), and WA%. Responder and non-responder subgroup analysis according to minimum clinically important difference (MCID) which was defined as an improvement of 15% in forced expiratory volume in 1 s (FEV₁) and 26 m in 6 min walk distance (6MWD) was conducted.

Results: Of the 19 patients, 11 were treated with EBV and 8 with IBV. In ipsilateral non-target lobes, WT% decreased significantly in 3rd-generation bronchi at 1 month, 3, and 6 months, as well as their WA% at 1 month and 6 months. Non-responders, who were unable to achieve MCID, showed no consistent bronchial wall changes. And their LA of 3rd-generation bronchi decreased especially at 1 month. After BLVR, the target lobe volume decreased significantly until 12 months of follow-up. The volume of ipsilateral lobes could increase correspondingly and achieve the best improvements at 6 months. The contralateral lung volume showed slight amelioration but there was no statistical significance.

Conclusions: Both airway structures and lung volumes showed changes after BLVR. The 3rd- and 4th-bronchial walls tend to be thinner, which were consistent with clinical improvements. Further studies are needed to prove this conclusion and find detect potential mechanics.

Keywords: Bronchoscopic lung volume reduction (BLVR); valves; quantitative CT; severe emphysema

Submitted Nov 02, 2021. Accepted for publication May 09, 2022.

doi: 10.21037/jtd-21-1734

View this article at: <https://dx.doi.org/10.21037/jtd-21-1734>

Introduction

In recent decades, bronchoscopic lung volume reduction (BLVR) with one-way valves has been shown to improve lung function, exercise capacity, and quality of life in patients with severe emphysema (1-8).

BLVR can cause target lobe volume reduction (TLVR) (9,10), and a TLVR of 350 mL measured by quantitative high-resolution CT (HRCT) analysis is assumed to be clinically significant (11). Even though recent studies showed the cut-off value for TLVR should be higher (12,13). However, variability in clinical outcomes has been observed, which warrants further research to investigate the other mechanisms or predictors of BLVR. It is commonly believed that with reduction of volume in the target lobe, the compressed, less diseased lobes will expand correspondingly. Then, it is rational that the airway may be dilated with pleural cavity pressure reduction and the improvement of dynamic airway compression following successful BLVR. Unfortunately, there are few studies illustrated that. Could the airway structure change with the treatment of valve volume reduction? Answering this question will help clarify the mechanism of BLVR and may determine parameters to predict responsiveness to treatment. We have observed several patients treated with BLVR experiencing intraluminal area (LA) enlargement and percentage of wall area (WA%) attenuation in the non-target bronchi (14). Therefore, we hypothesized that the airway structures changed after BLVR, and these changes may contribute to clinical benefits.

The objective of the present study was to detect the bronchial changes after BLVR and find the relationship between these changes and clinical benefits. We present the following article in accordance with the STROBE reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1734/rc>).

Methods

Study design and patients

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was retrospective, so no informed consent was signed. A total of all 24 patients with advanced emphysema who underwent BLVR with valves [both Zephyr endobronchial valve (EBV) and the intrabronchial valve (IBV) system] at Peking University First Hospital, Beijing, China, between January 2010 and June 2018 were included in the study. Inclusion criteria

were age over 40 years, nonsmoker status for at least three months, severe airflow obstruction [post-bronchodilator forced expiratory volume in 1 s (FEV₁) <50% of predicted], hyperinflation [total lung capacity (TLC) >100% of predicted and residual volume (RV) >150% of predicted], heterogeneous emphysema (heterogeneity compared to the ipsilateral lobe \geq 15% difference), and an intact interlobar fissure (\geq 90% complete). Chartis system was conducted for patients who received EBV therapy during surgery to evaluate the absence of collateral ventilation (CV) (1,2,15). Patients with severe pulmonary hypertension, diffusion capacity less than 20%, or severe comorbidities were excluded from the BLVR. HRCT with consolidations other than the target lobe, pneumothorax, or pleural effusion were excluded. Data collection included medical history, symptoms, modified Medical Research Council (mMRC) dyspnea scale, pulmonary function tests, 6 min walk distance (6MWD), and HRCT at pre-operation and at 1 month, 3, 6, and 12 months of follow-up. The study design was approved by the ethics committee of the Peking University First Hospital (No. 201971).

Pulmonary function tests

Pulmonary function tests (spirometry and body plethysmography) for FEV₁, FVC (post-bronchodilator), TLC, RV, and percentages of predicted values were performed according to ATS/ERS guidelines. The baseline pulmonary function tests were completed three days before BLVR.

3D-CT analysis

An automatic analysis software (SYNAPSE VINCENT; Fuji Film, Tokyo, Japan) was used to reconstruct and analyze the HRCT images performed at full inspiration.

Airway

All the second-(lobar), third-(segmental), and fourth-(sub-segmental) bronchi were evaluated. Five parameters, including wall thickness (WT) and percentage of wall thickness (WT%), LA, wall area (WA), and WA% at the midpoint of each level of airways were calculated automatically and then the median of these parameters were used to subsequent analysis (*Figure 1*). Bronchi with bronchiectasis were not calculated.

Emphysema and volume

The percentage of low attenuation area (LAA%) was used




Figure 1 Bronchial structure measured in 3D-CT. (A) 2nd- to 4th-generation bronchi before BLVR; (B) 3rd-generation bronchial parameters before BLVR; (C) 2nd- to 4th-generation bronchi after BLVR; (D) 4th-generation bronchial parameters after BLVR. BLVR, bronchoscopic lung volume reduction.

to evaluate the degree of emphysema, which was defined as the proportion below the CT density threshold of -950 Hounsfield units (HU). It was automatically calculated for the whole lung and for each lobe. Changes in the volume of all lobes, including the target lobe, non-target ipsilateral lobes, and contralateral lobes, were also quantified.

Outcomes

The primary outcomes were changes in WT, WT%, LA, WA, WA% of 2nd- to 4th-generation airways in the target lobe, ipsilateral non-target lobes, and contralateral lobes

from baseline to 1-, 3-, 6-, and 12-month follow-up.

The secondary outcomes were changes in target lobe volume (TLV), ipsilateral lobe volume (ILV), and contralateral lobe volume (CLV) from baseline to the 1-, 3-, 6-, and 12-month follow-up.

Statistical analyses

SPSS version 24 (IBM, USA) was used for the statistical analyses. Given the small sample size, data were expressed as median [interquartile range (IQR)] by missing the condition of normal distribution. The Wilcoxon signed-

rank test and Wilcoxon rank sum test were used to test the in-group differences as appropriate. Statistical significance was set at $P < 0.05$.

Results

Patients and procedural details

A total of 24 patients underwent BLVR with valves between January 2010 and June 2018. Five patients were excluded: 1 patient received valve removal due to a target lobe infection and 4 dropped out after treatment. Thus, 19 patients were included. Eleven of 19 patients were treated with EBV and 8 were treated with IBV. Patient characteristics were summarized in *Table 1*. FEV_1 was 0.60 (0.47–0.79) L, $FEV_1(\%Pred)$ was 24.50% (18.60–29.63)%, TLC (%Pred) was 138.90% (129.50–144.30)% and RV(%Pred) was 279.60% (256.50–295.80)% at baseline. Patients treated with EBV were more severe. Four pneumothorax and 5 acute exacerbations (AEs) occurred up to 12 months after BLVR.

Paired data analyses showed that FEV_1 , FVC, 6MWD, and mMRC improved significantly at 1 month after therapy. However, these benefits faded at 12 months (see *Table 1*). Patients who treated with EBV had a better 6MWD improvement than patients treated with IBV (see *Tables S1,S2*).

Primary outcomes

Changes in airway structures

The target lobe bronchi could not be extracted effectively because of atelectasis after treatment. Thus, only the non-target lobes were measured. The WT, WT%, LA, WA and WA% of 2nd- to 4th-generation bronchi were showed in *Table 2*. After BLVR, in ipsilateral non-target lobes, WT and WA showed a decrease, but the significance was only observed in the bronchi of 3rd- and 4th-generation at 1 month. WT% was reduced significantly in 3rd-generation bronchi at 1 month [–2.00% (–9.50 to 2.00)%], 3 months [–3.00% (–8.00 to 2.00)%], and 6 months [–6.00% (–9.00 to –2.00)%], as did their WA% at 1 month [–5.00% (–13.00 to 2.50)%] and 6 months [–8.00% (–14.00 to –2.00)%], respectively. Changes in LA were ambiguous and varied at different time points without statistical significance (see in *Table 3*).

Compared with ipsilateral bronchi, changes of contralateral bronchi structures were slight (see *Table 4*). The WT% of 4th-generation decreased significantly by –1.00%

(–5.00 to 2.00)% and WA% of 4th-generation decreased by –2.00% (–6.00 to 3.00)% at 6 months after BLVR but raised back at 12 months. It was worth noting that LA of 3rd-generation showed continuous enlargement after BLVR and achieved the largest level at 6 months [increased by 3.60 (–2.60 to 7.80) mm²].

Both EBV and IBV groups showed a tendency to decrease in WT, WT%, WA (except at 6 months), and WA% of 3rd-generation up to 6 months of follow-up in ipsilateral bronchi. However, these changes in the EBV group were more significant at 1 month while in the IBV group at 6 months (see in *Table S3*).

Subgroup analysis

The minimum clinically important difference (MCID) for FEV_1 and 6MWD in the treatment of patients with severe emphysema has been established in previous studies (16,17). An improvement of 15% in FEV_1 and 26 m in 6MWD was assumed to be clinically significant. In our study, patients who met both criteria were defined as responders (responder group, n=9), otherwise as non-responders (non-responder group, n=10). To evaluate whether the airway structures changes contribute to the responsiveness of therapy, subgroup analysis of 2nd- to 4th-generation airways of non-target lobes was conducted based on the primary endpoint results.

In responder group, WT% and WA% of 3rd-generation ipsilateral bronchi at 1, 3, and 6 months decreased (*Figure 2*), as well as the WT, WT%, WA, and WA% in 4th-generation bronchi at 1 month (*Figure 3*), whereas such changes were not observed in non-responder group. LA of 3rd-generation bronchi decreased especially at 1 month in non-responder group (*Figure 2C*). In contralateral bronchi, WT% and WA% showed a significant decrease only in 4th-generation at 6 months after therapy (see *Table S4*).

Secondary outcomes

After BLVR, the target lobe volume decreased –613.70 (–1,451.78 to –154.40) mL at 1 month, –913.50 (–1,462.08 to –338.18) mL at 3 months, –1,163.00 (–1,525.90 to –525.30) mL at 6 months, and –715.30 (–1,525.90 to –378.50) mL at 12 months. Meanwhile, the volume of ipsilateral lobes increased moderately consistent with them and achieved best improvements at 6 months (median change: 470.40 mL). The contralateral lobes also showed slight amelioration but there was no statistical significance (see in *Table 5*).

Table 1 Clinic characteristics and outcomes before and after BLVR

Variables	Value	Changes after BLVR			
		1 month (n=15)	P	12 months (n=13)	P
Age, year	63.00 (52.00 to 66.00)				
Male sex, No. (%)	19 (100.00)				
Lung function					
FEV ₁ (L)	0.60 (0.47 to 0.79)	0.12 (0.04 to 0.25)	0.005	0.00 (−0.09 to 0.07)	0.969
FEV ₁ (%Pred)	24.50 (18.60 to 29.63)	3.00 (0.80 to 8.10)	0.017	0.01 (−2.95 to 5.20)	0.625
FVC (L)	1.93 (1.63 to 2.44)	0.47 (0.23 to 0.78)	0.001	0.10 (−0.04 to 0.56)	0.074
FVC (%Pred)	48.70 (36.80 to 65.30)				
FEV ₁ /FVC, %	30.71 (26.06 to 35.36)				
TLC (L)	9.03 (7.97 to 9.43)	−0.66 (−0.98 to 0.82)	0.426	−0.12 (−0.71 to 0.33)	0.552
TLC (%Pred)	138.90 (129.50 to 144.30)				
RV (L)	6.74 (5.87 to 7.21)	−0.96 (−1.61 to −0.65)	0.078	−0.12 (−0.98 to 0.35)	0.311
RV (%Pred)	279.60 (256.50 to 295.80)				
6MWD (m)	279.00 (170.00 to 384.00)	120.00 (13.00 to 157.00)	0.005	49.00 (−124.00 to 129.00)	0.594
mMRC scale	3.00 (3.00 to 3.75)	−1.00 (−1.00 to 0.00)	0.021	0.00 (−0.25 to 1.25)	0.785
TLV, mL	1,837.45 (1,377.98 to 2,223.88)				
Target lobe LAA%	34.40 (27.85 to 55.88)				
Valve					
EBV, No. (%)	11 (57.89)				
IBV, No. (%)	9 (47.37)				
No. per patient	3.00 (3.00 to 4.00)				
Site, No. (%)					
RUL	6 (31.58)				
RML	3 (15.79)				
RLL	1 (5.26)				
LUL	6 (31.58)				
LLL	3 (15.79)				

Data are presented as median (Q1 to Q3) unless otherwise noted. BLVR, bronchoscopic lung volume reduction; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; 6MWD, 6-min walk distance; mMRC, modified Medical Research Council; TLV, target lobe volume; LAA%, percentage of low attenuation area; EBV, endobronchial valve; IBV, intrabronchial valve; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.

Discussion

Our study showed that BLVR can cause mechanical changes in patients with severe emphysema. In addition to inducing a volume shift from the target lobe to non-target lobes, bronchial thickness and lumen area can be ameliorated

bilaterally. Responsiveness to valve therapy correlates with changes in the bronchial structure.

Initially, it was believed that the clinical benefits in BLVR with valves for advanced emphysema came mainly from the results of volume reduction in the diseased lobe and thus provide more space to more functional lobes. It

Table 2 Baseline ipsilateral and contralateral airway structures

Variables	Ipsilateral airway			Contralateral airway		
	2nd-	3rd-	4th-	2nd-	3rd-	4th-
WT (mm)	1.15 (0.90 to 1.75)	0.94 (0.73 to 1.17)	0.74 (0.61 to 1.01)	1.03 (0.78 to 2.07)	0.86 (0.70 to 1.12)	0.69 (0.59 to 0.89)
WT%	22.00 (16.00 to 26.75)	29.00 (24.00 to 35.50)	33.00 (30.00 to 36.00)	21.00 (16.00 to 29.00)	30.00 (24.00 to 35.00)	33.00 (30.00 to 35.00)
LA (mm ²)	65.30 (51.10 to 88.60)	18.00 (11.85 to 29.10)	7.65 (5.13 to 13.58)	76.60 (48.10 to 90.90)	15.85 (10.63 to 26.75)	7.50 (4.90 to 10.75)
WA (mm ²)	38.80 (20.70 to 67.05)	18.55 (11.70 to 24.40)	9.40 (6.35 to 16.70)	37.30 (19.00 to 77.90)	15.90 (11.40 to 23.05)	8.70 (6.10 to 13.15)
WA%	38.50 (29.00 to 45.25)	49.50 (43.00 to 58.00)	55.00 (51.00 to 59.00)	37.00 (30.00 to 48.00)	51.00 (42.00 to 57.75)	54.50 (51.00 to 58.25)

Data are presented as median (Q1 to Q3). WT, wall thickness; WT%, percentage of wall thickness; LA, intraluminal area; WA, wall area; WA%, percentage of wall area.

Table 3 Ipsilateral airway changes after BLVR

Variables	1-month	P	3-month	P	6-month	P	12-month	P
ΔWT (mm)								
2nd-	-0.04 (-0.27 to 0.46)	0.904	-0.11 (-0.56 to 0.31)	0.435	-0.36 (-1.19 to -0.01)	0.069	-0.20 (-0.89 to 0.36)	0.388
3rd-	-0.06 (-0.29 to 0.04)	0.005	-0.03 (-0.38 to 0.15)	0.145	-0.14 (-0.35 to 0.09)	0.015	-0.06 (-0.36 to 0.15)	0.201
4th-	-0.07 (-0.28 to 0.09)	0.010	0.03 (-0.21 to 0.13)	0.988	0.02 (-0.11 to 0.13)	0.918	-0.04 (-0.14 to 0.09)	0.386
ΔWT%								
2nd-	0.00 (-3.00 to 5.00)	0.704	-2.00 (-6.00 to 2.50)	0.169	-3.50 (-11.25 to 1.00)	0.091	-1.50 (-9.00 to 5.50)	0.533
3rd-	-2.00 (-9.50 to 2.00)	0.012	-3.00 (-8.00 to 2.00)	0.049	-6.00 (-9.00 to -2.00)	0.006	-2.50 (-8.75 to 4.75)	0.223
4th-	-1.00 (-3.00 to 2.00)	0.317	0.00 (-2.00 to 3.00)	0.838	0.00 (-6.50 to 2.00)	0.426	0.50 (-3.00 to 7.25)	0.271
ΔLA (mm²)								
2nd-	2.70 (-11.60 to 15.00)	0.778	4.30 (-17.45 to 27.30)	0.463	-10.40 (-36.08 to 10.40)	0.401	-2.15 (-23.53 to 7.85)	0.695
3rd-	-1.00 (-4.55 to 5.00)	0.936	1.50 (-2.25 to 6.25)	0.211	1.30 (-0.90 to 9.70)	0.156	-2.35 (-4.55 to 3.73)	0.808
4th-	-1.00 (-2.95 to 0.78)	0.060	0.00 (-2.30 to 2.90)	0.833	0.15 (-2.78 to 4.03)	0.933	-0.65 (-6.48 to 2.55)	0.204
ΔWA (mm²)								
2nd-	-0.20 (-12.30 to 18.20)	0.904	-2.40 (-22.35 to 17.55)	0.619	-12.65 (-62.75 to -0.80)	0.123	-10.65 (-37.40 to 11.83)	0.272
3rd-	-2.4 (-6.45 to 1.60)	0.011	-1.10 (-9.25 to 4.85)	0.219	-2.50 (-7.10 to 5.20)	0.363	-1.40 (-9.68 to 5.50)	0.458
4th-	-1.20 (-4.73 to 1.63)	0.028	-0.10 (-3.30 to 3.60)	0.992	0.25 (-3.43 to 3.53)	0.991	-1.15 (-6.18 to 2.03)	0.124
ΔWA%								
2nd-	-1.00 (-4.00 to 6.00)	1.000	-5.00 (-10.00 to 3.00)	0.130	-6.00 (-16.75 to 0.00)	0.046	-3.00 (-14.00 to 8.00)	0.479
3rd-	-5.00 (-13.00 to 2.50)	0.011	-4.00 (-12.00 to 3.50)	0.058	-8.00 (-14.00 to -2.00)	0.005	-3.50 (-11.75 to 7.50)	0.224
4th-	0.00 (-4.75 to 3.00)	0.417	0.00 (-3.00 to 5.00)	0.872	0.00 (-8.25 to 3.00)	0.338	0.50 (-4.00 to 9.50)	0.383

Data are presented as median (Q1 to Q3). BLVR, bronchoscopic lung volume reduction; WT, wall thickness; WT%, percentage of wall thickness; LA, intraluminal area; WA, wall area; WA%, percentage of wall area.

Table 4 Contralateral airway changes after BLVR

Variables	1-month	3-month	6-month	12-month
Δ WT (mm)				
2nd-	0.06 (–0.20 to 0.37)	0.03 (–0.32 to 0.35)	–0.07 (–0.65 to 0.06)	–0.01 (–0.23 to 0.12)
3rd-	0.02 (–0.18 to 0.33)	0.05 (–0.14 to 0.26)	–0.02 (–0.24 to 0.19)	0.09 (–0.13 to 0.34)
4th-	0.02 (–0.14 to 0.11)	–0.01 (–0.12 to 0.12)	–0.02 (–0.24 to 0.12)	–0.01 (–0.17 to 0.13)
Δ WT%				
2nd-	0.00 (–2.75 to 4.25)	–1.00 (–6.00 to 4.50)	–1.00 (–4.50 to 1.50)	0.00 (–4.50 to 2.75)
3rd-	0.00 (–5.25 to 7.00)	0.00 (–3.00 to 7.25)	–2.00 (–7.00 to 5.00)	2.00 (–5.00 to 8.00)
4th-	0.00 (–4.00 to 4.00)	0.00 (–3.00 to 4.00)	–1.00 (–5.00 to 2.00)*	1.00 (–3.75 to 3.00)
Δ LA (mm ²)				
2nd-	0.70 (–7.75 to 5.40)	–3.10 (–14.65 to 6.45)	–3.70 (–19.00 to 3.90)	–0.40 (–5.40 to 8.95)
3rd-	0.15 (–4.28 to 4.45)	1.00 (–3.03 to 5.38)	3.60 (–2.60 to 7.80)*	0.40 (–6.10 to 5.70)
4th-	0.10 (–1.82 to 2.22)	0.00 (–1.80 to 1.50)	0.30 (–2.00 to 3.20)	–0.15 (–1.78 to 1.38)
Δ WA (mm ²)				
2nd-	1.90 (–8.35 to 9.73)	3.10 (–19.85 to 15.90)	–1.80 (–38.30 to 1.45)	0.10 (–9.25 to 3.18)
3rd-	–0.40 (–4.40 to 8.10)	1.15 (–3.88 to 7.33)	–1.10 (–5.10 to 5.20)	2.00 (–2.20 to 8.80)
4th-	0.00 (–2.43 to 2.50)	–0.10 (–2.80 to 2.40)	0.10 (–4.00 to 2.30)	–0.50 (–3.78 to 1.85)
Δ WA%				
2nd-	0.00 (–4.00 to 7.50)	–2.00 (–9.00 to 6.50)	–1.00 (–7.50 to 2.00)	0.00 (–6.50 to 4.50)
3rd-	1.00 (–7.25 to 10.25)	0.00 (–4.00 to 7.25)	–2.00 (–9.00 to 4.00)	–1.00 (–6.00 to 12.00)
4th-	0.00 (–5.00 to 5.00)	0.00 (–4.00 to 5.00)	–2.00 (–6.00 to 3.00)*	1.50 (–3.75 to 4.00)

Data are presented as median (Q1 to Q3). *, indicate $P < 0.05$. WT, wall thickness; WT%, percentage of wall thickness; LA, intraluminal area; WA, wall area; WA%, percentage of wall area.

has been proven that patients with lobar atelectasis, even those with pneumothorax, had a higher response rate in lung function parameters (1,3,11,18). In recent years, more studies have focused on other potential mechanisms and predictors of BLVR. In 2013, Argula found that baseline regional perfusion could affect responsiveness to BLVR (19). Patients with low target lobe perfusion at baseline showed a greater improvement in exercise capacity with EBV therapy. Correspondingly, Thomsen revealed that patients with high ipsilateral non-target lobe perfusion demonstrated greater improvements in the 6MWD (20). In contrast to these earlier findings, the airway structures before and after therapy has not been studied previously. Although it is rational that volume reduction may induce compressed airway dilation, there is no direct evidence for this. We had reported the results of quantitative CT assessment after

BLVR on chest congress but with only 4 cases included (14). In the 4 patients, LA enlargement and WA% attenuation were observed in the non-target bronchi.

In the present study, we observed meaningful changes in airways measured using 3D-CT images after BLVR. The wall of 2nd- to 4th-generation airways tended to become thinner after the procedure. In the responder group, all parameters of ipsilateral non-target 3rd- and 4th-generation bronchial WT decreased significantly after 1 month as well as WT% and WA% at 3 and 6 months, whereas no significant changes occurred in the non-responder group. However, further correlation analysis was not conducted given that only less than 15 patients were included in the follow up. Thickening of small airway walls, one of the most important features of chronic obstructive pulmonary disease (COPD), is thought to be a combination of inflammatory




Figure 2 Ipsilateral 3rd-generation airway structure changes in Responder group and non-Responder group after BLVR. (A) Changes in WT after therapy; (B) changes in WT% after therapy; (C) changes in LA after therapy; (D) changes in WA after therapy; (E) changes in WA% after therapy. Data were used as median (Q1–Q3). *, $P < 0.05$. WT, wall thickness; WT%, percentage of wall thickness; LA, intraluminal area; WA, wall area; WA%, percentage of wall area; BLVR, bronchoscopic lung volume reduction.




Figure 3 Ipsilateral 4th-generation airway structure changes in Responder group and non-Responder group after BLVR. (A) changes in WT after therapy; (B) changes in WT% after therapy; (C) changes in LA after therapy; (D) changes in WA after therapy; (E) changes in WA% after therapy. Data were used as median (Q1–Q3). *, $P < 0.05$; **, $P < 0.01$. WT, wall thickness; WT%, percentage of wall thickness; LA, intraluminal area; WA, wall area; WA%, percentage of wall area; BLVR, bronchoscopic lung volume reduction.

Table 5 Changes in volume of lobes

Variables	1-month (N=14)	3-month (N=14)	6-month (N=13)	12-month (N=11)
ΔTLV (mL)	-613.70 (-1,451.78 to -154.40)	-913.50 (-1,462.08 to -338.18)	-1,163.00 (-1,525.90 to -525.30)	-715.30 (-1,525.90 to -378.50)
P	0.003	0.001	0.018	0.004
ΔILV (mL)	108.05 (-52.55 to 303.40)	90.10 (16.20 to 335.70)	470.40 (123.65 to 1,056.90)	88.70 (-128.40 to 525.00)
P	0.157	0.044	0.028	0.101
ΔCLV (mL)	131.10 (26.43 to 254.73)	116.45 (-169.70 to 301.63)	126.70 (-456.85 to 943.45)	169.80 (-519.45 to 359.35)
P	0.064	0.433	0.327	0.638

Data are presented as median (Q1 to Q3). TLV, target lobe volume; ILV, ipsilateral lobes volume; CLV, contralateral lobes volume.

changes, constrictions, and remodeling. It remained unclear how airway structure changes after BLVR. One possible reason was that the compressed and less diseased ipsilateral lobes expanded after BLVR (as shown in *Table 5*), bronchi then changed correspondingly, which could lead to mechanic improvements. The bronchi measured in our study were larger airways (2nd- to 4th-generation). Earlier findings proved the relationship between the morphology of the central airways and distal small airways, which were the sites of airway obstruction in COPD (21). Recently, several studies have examined the relationship between the wall or intraluminal area of 3rd- to 6th-generation airways on CT and clinical features. Grydeland demonstrated that airway wall thickening was positively correlated with respiratory symptoms (22). Mohamed reported that airway WT was independently associated with a lower FEV₁ after an average 3-year follow-up period (23). Karayama showed that both WT and intraluminal area were correlated with FEV₁ (24). A noteworthy finding was that the effect was not only present at the ipsilateral lobes of the treatment but was also observed in the contralateral lobes. This implied that BLVR may have pan-pulmonary effects. Thus, valve therapy may play a significant role in alleviating local or pan-pulmonary disturbances in mechanics. Additionally, the reduction of the bronchial wall may have other mechanisms, such as the reduction of smooth muscles and the inhibition of edema or hyperplasia of the mucus membrane by inflammation reduction, although there was no evidence. More rigorous studies would be needed to provide further insights.

An important negative finding was that LA showed no consistent enlargement in our study. One possible explanation is that 2nd- to 4th-generation bronchi have cartilages, which may limit their enlargement to some extent. As small airways lack cartilage, we could expect that

non-supported bronchi or bronchioles might be dilated with the reduction of pleural pressure, and thus airflow limitation was improved. As a limitation of the methodology, we could not analyze structural changes in these smaller airways. In the future, more sensitive imaging methodologies should be used to elucidate changes in precision.

We also assessed the volume changes in target lobes, non-target ipsilateral lobes, and contralateral lobes. Coxson reported a volume decrease in the treated upper lobe and an increase in the untreated non-upper lobes after IBV therapy at 6 months (9). The Endobronchial Valve for Emphysema Palliation Trial (VENT) study showed similar changes in patients with EBV therapy (1). Our analysis supports the observations of previous studies. It was showed that nontarget ipsilateral lobes acquired the largest increase in volume. This complies with the rationale for the lung volume reduction procedures. For the contralateral lobes, we only observed varying but insignificant increases. In addition, a decrease in target lobes was observed up to 12 months after treatment (*Table 5*).

Furthermore, we found that EBV seems to have a more rapid effect on bronchial wall thinning than IBV. This may be partly explained by the study design. The EBV data were obtained from patients in a real hospital setting. These patients seemed to be more severe, with lower FEV₁, shorter distance of 6MWD, and higher mMRC scale, even than those reported in most published studies (1,2,4,25). IBV data were obtained from the REACH study, which is a randomized controlled trial. Thus, the baseline parameters in EBV group were worse than those in IBV group. Another noticeable reason is the possible difference in the mechanism between EBV and IBV. However, there was no convincing evidence given that the sample size was too small, and the baseline characters did not match. It is

necessary to conduct further head-to-head trials with larger sample size to evaluate whether there are any differences in responses between EBV and IBV.

Our study has some limitations. Firstly, the small sample size resulted in insufficient power to explain the outcomes. Secondly, all measurement and analysis of quantitative CT were based on normal inspiratory CT, rather end-inspiratory CT guided by spirometer. Given that patients with severe emphysema would present dyspnea in all probability, the degree of emphysema and bronchitis in CT would be underestimate or overestimate. Furthermore, the techniques we used could only identify and construct airways with inner diameters greater than 2 mm, which include the 5th generation or larger bronchi. Even if it was feasible, the analysis of such is more challenging than in advanced emphysema because bronchi in these patients are frequently twisted.

In conclusion, patients with severe emphysema could benefit from BLVR. In addition to volume reduction, bronchial structures, especially in 3rd- and 4th-generation show changes after the therapy. Our report provided a preliminary basis for BLVR mechanics. Further studies are needed to elucidate the mechanisms and structural changes of the smaller bronchi.

Acknowledgments

Part of the result of our study was reported in ATS2020 entitled “Different Airway Structure Changes on Computed Tomography and Efficacy after Bronchoscopic Lung Volume Reduction Using Two Different Valves Respectively for Advanced Chronic Obstructive Pulmonary Disease”: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A5042.

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1734/rc>

Data Sharing Statement: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1734/dss>

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1734/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1734/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study design was approved by the ethics committee of the Peking University First Hospital (No. 201971). This study was retrospective, so no informed consent was signed.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Sciruba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. *N Engl J Med* 2010;363:1233-44.
2. Davey C, Zoumot Z, Jordan S, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HiFi study): a randomised controlled trial. *Lancet* 2015;386:1066-73.
3. Herth FJ, Noppen M, Valipour A, et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. *Eur Respir J* 2012;39:1334-42.
4. Ninane V, Geltner C, Bezzi M, et al. Multicentre European study for the treatment of advanced emphysema with bronchial valves. *Eur Respir J* 2012;39:1319-25.
5. Klooster K, ten Hacken NH, Hartman JE, et al. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. *N Engl J Med* 2015;373:2325-35.
6. Hartman JE, Klooster K, Slebos DJ, et al. Improvement of physical activity after endobronchial valve treatment in

- emphysema patients. *Respir Med* 2016;117:116-21.
7. Gompelmann D, Benjamin N, Bischoff E, et al. Survival after Endoscopic Valve Therapy in Patients with Severe Emphysema. *Respiration* 2019;97:145-52.
 8. Li S, Wang G, Wang C, et al. The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema. *Respiration* 2019;97:416-27.
 9. Coxson HO, Nasute Fauerbach PV, Storness-Bliss C, et al. Computed tomography assessment of lung volume changes after bronchial valve treatment. *Eur Respir J* 2008;32:1443-50.
 10. Mata J, Altes T, Truwit J, et al. Characterization and detection of physiologic lung changes before and after placement of bronchial valves using hyperpolarized helium-3 MR imaging: preliminary study. *Acad Radiol* 2011;18:1195-9.
 11. Herth FJ, Eberhardt R, Gompelmann D, et al. Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment. *Eur Respir J* 2013;41:302-8.
 12. Gompelmann D, Kontogianni K, Schuhmann M, et al. The minimal important difference for target lobe volume reduction after endoscopic valve therapy. *Int J Chron Obstruct Pulmon Dis* 2018;13:465-72.
 13. Welling JBA, Hartman JE, van Rikxoort EM, et al. Minimal important difference of target lobar volume reduction after endobronchial valve treatment for emphysema. *Respirology* 2018;23:306-10.
 14. Huang JF, Rui W, Qiu JX. Quantitative CT Assessment of Bronchoscopic Lung Volume Reduction With Valve. *Chest* 2014;145:361A.
 15. Gompelmann D, Eberhardt R, Slebos DJ, et al. Diagnostic performance comparison of the Chartis System and high-resolution computerized tomography fissure analysis for planning endoscopic lung volume reduction. *Respirology* 2014;19:524-30.
 16. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J* 2008;31:416-69.
 17. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. *Eur Respir J* 2011;37:784-90.
 18. Gompelmann D, Benjamin N, Kontogianni K, et al. Clinical and radiological outcome following pneumothorax after endoscopic lung volume reduction with valves. *Int J Chron Obstruct Pulmon Dis* 2016;11:3093-9.
 19. Argula RG, Strange C, Ramakrishnan V, et al. Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema. *Chest* 2013;144:1578-86.
 20. Thomsen C, Theilig D, Herzog D, et al. Lung perfusion and emphysema distribution affect the outcome of endobronchial valve therapy. *Int J Chron Obstruct Pulmon Dis* 2016;11:1245-59.
 21. Nakano Y, Wong JC, de Jong PA, et al. The prediction of small airway dimensions using computed tomography. *Am J Respir Crit Care Med* 2005;171:142-6.
 22. Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. *Am J Respir Crit Care Med* 2010;181:353-9.
 23. Mohamed Hoesein FA, de Jong PA, Lammers JW, et al. Airway wall thickness associated with forced expiratory volume in 1 second decline and development of airflow limitation. *Eur Respir J* 2015;45:644-51.
 24. Karayama M, Inui N, Mori K, et al. Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD. *Sci Rep* 2017;7:41709.
 25. Valipour A, Slebos DJ, Herth F, et al. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. *Am J Respir Crit Care Med* 2016;194:1073-82.

Cite this article as: Guo F, Huang J, Hu Y, Qiu J, Zhang H, Zhang W, Cheng Y, Liao J, Wang G. Clinical outcomes and quantitative CT analysis after bronchoscopic lung volume reduction using valves for advanced emphysema. *J Thorac Dis* 2022;14(6):1922-1932. doi: 10.21037/jtd-21-1734

Table S1 Clinic Characteristics in patients received different valves

Variables	Groups		p value
	EBV(n=11)	IBV(n=8)	
Age-year	57.00(52.00-67.00)	63.00(53.25-66.00)	0.657
Male sex-no. (%)	11(100%)	8(100%)	-
Lung function			
FEV ₁ (L)	0.56(0.45-0.60)	0.74(0.64-0.89)	0.041
FEV ₁ (%pred)	21.50(18.60-29.63)	27.40(19.63-29.88)	0.492
FVC(L)	1.82(1.63-2.04)	2.32(1.54-3.13)	0.206
FVC(%pred)	43.80(35.90-51.60)	60.75(50.28-79.50)	0.026
FEV ₁ /FVC-%	32.65(26.06-35.36)	29.97(25.31-35.73)	0.840
TLC(L)	9.15(7.86-9.44)	8.92(8.01-9.22)	0.657
TLC(%pred)	149.10(120.80-149.20)	136.35(132.33-143.93)	0.840
RV(L)	7.10(6.00-7.35)	6.21(5.85-6.86)	0.206
RV(%pred)	290.90(279.00-348.40)	257.95(235.05-284.70)	0.062
6MWD(m)	170.00(120.00-230.00)	392.00(328.50-427.25)	<0.001
mMRC scale	3.50(3.00-4.00)	3.00(2.00-3.00)	0.021
TLV-ml	1817.70(1039.70-2281.38)	1837.45(1528.70-2160.68)	0.829
Target lobe LAA%	51.45(28.65-56.35)	32.40(27.75-52.15)	0.633

Data are presented as median (Q1-Q3) unless otherwise noted. FEV₁=forced expiratory volume in 1s; FVC=forced vital capacity; TLC= total lung capacity; RV=residual volume;6MWD=6-min walk distance; mMRC=modified Medical Research Council; TLV= Target lobe volume; LAA%= percentage of low attenuation area; EBV= Endobronchial Valve; IBV= Intrabronchial Valve.

Table S2 Clinic outcomes in patients treated with different valves

Outcome (Median change)	1-Month			12-Month		
	EBV (n=10)	IBV (n=5)	P value	EBV (n=6)	IBV (n=7)	P value
Lung function						
ΔFEV1 (L)	0.12 (0.04–0.29)	0.08 (0.05–0.22)	0.679	0.02 (–0.14–0.12)	0.00 (–0.08–0.06)	0.836
ΔFEV1-%	25.83 (7.15–54.52)	10.00 (5.43–38.30)	0.594	2.96 (–19.13–29.23)	0.00 (–10.13–6.52)	0.836
ΔFEV ₁ (pred%)	2.8 (–0.50–8.45)	3.00 (1.70–7.55)	0.679	0.95 (–4.73–10.58)	0.10 (–2.20–2.10)	0.731
ΔFVC (L)	0.69 (0.19–0.93)	0.34 (0.09–0.42)	0.129	0.37 (0.16–0.83)	0.10 (–0.10–0.10)	0.138
ΔTLC (L)	–0.57 (–1.19–1.34)	–0.78 (–1.33–0.08)	0.440	0.26 (–1.13–1.27)	–0.15 (–0.50–0.09)	0.445
ΔRV (L)	–1.04 (–1.69–0.05)	–0.94 (–1.48––0.21)	0.859	–0.16 (–1.51–1.35)	–0.02 (–0.11––0.01)	0.836
Δ6MWD-m	150.00 (84.00–169.50)	–5 (–74–106)	0.019	145.50 (69.00–204.00)	–50.00 (–153.00–113)	0.024
Δ6MWD-%	45.24 (25.71–55.29)	–1.12 (–23.8–22.12)	0.008	58.12 (21.37–115.46)	–11.11 (–37.05–28.25)	0.042
ΔmMRC	–1.00 (–2.00–1.00)	0 (–1.00–0.50)	0.052	– ^a	– ^a	
ΔmMRC-%	–33.33 (–54.17––25.00)	0 (–33.33–16.67)	0.126	– ^a	– ^a	

Data are Presented as median (Q25 - Q75) unless otherwise noted. ^a, lost follow up. See *Table S1* legends for expansion of other abbreviations.

Table S3 Subgroup Analysis: changes of ipsilateral airway in EBV and IBV groups

		1-month	P	3-month	P	6-month	P	12-month	P
ΔWT (mm)									
3rd-	EBV	-0.10 (-0.60-0.07)*	0.454	-0.02 (-0.42-0.21)	0.751	-0.14 (-0.25-0.10)	0.358	-0.02 (-0.14-0.22)	0.278
	IBV	-0.05 (-0.21-0.04)		-0.03 (-0.38-0.13)		-0.25 (-0.41--0.04)*		-0.16 (-0.43-0.13)	
4th-	EBV	-0.07 (-0.29-0.09)*	0.901	-0.01 (-0.22-0.11)	0.433	0.06 (-0.10-0.20)	0.431	-0.06 (-0.16-0.11)	0.450
	IBV	-0.08 (-0.26-0.06)		0.06 (-0.16-0.18)		0.01 (-0.11-0.11)		-0.02 (-0.11-0.08)	
ΔWT%									
3rd-	EBV	-5.00 (-12.00-1.00)**	0.043	-4.00 (-7.75-4.25)	0.874	-2.00 (-8.50-3.50)	0.243	0.50 (-5.00-6.00)	0.151
	IBV	-0.50 (-6.75-8.00)		-2.00 (-9.00-2.00)		-6.50 (-12.25--2.75)**		-4.50 (-9.75-1.75)	
4th-	EBV	-1.00 (-4.50-2.50)	0.782	0.00 (-3.00-3.00)	0.990	1.00 (-7.50-10.00)	0.537	2.00 (-2.00-8.00)	0.327
	IBV	-1.00 (-3.00-2.00)		0.00 (-2.00-3.00)		0.00 (-7.00-2.00)		-1.00 (-3.00-7.00)	
ΔLA (mm²)									
3rd-	EBV	1.60 (-1.50-9.90)	0.005	1.85 (-1.40-5.15)	0.653	2.50 (-0.20-22.75)	0.391	-3.70 (-5.63-3.20)	0.292
	IBV	-3.00 (-10.55-0.58)*		1.50 (-3.95-6.95)		-0.05 (-1.33-10.40)		-1.15 (-3.93-9.28)	
4th-	EBV	-0.50 (-2.20-1.30)	0.325	-0.80 (-2.40-3.10)	0.543	-1.80 (-12.20-5.05)	0.290	-7.00 (-10.80-3.10)	0.122
	IBV	-1.05 (-4.23-0.65)		0.75 (-1.85-2.80)		0.30 (-1.00-3.80)		0.00 (-3.00-2.50)	
ΔWA (mm²)									
3rd-	EBV	-2.40 (-10.90-2.80)	0.854	-0.30 (-10.85-6.88)	0.475	1.80 (-5.15-7.55)	0.327	-1.40 (-5.20-6.03)	0.770
	IBV	-2.45 (-4.95-0.35)*		-3.50 (-7.00-0.60)		-4.55 (-7.50-3.00)		-1.75 (-10.60-5.75)	
4th-	EBV	-1.00 (-5.15-2.00)	0.863	-0.20 (-3.80-4.10)	0.768	0.20 (-2.80-4.60)	0.961	-6.40 (-8.50-1.80)	0.118
	IBV	-1.40 (-4.35-1.03)		0.45 (-3.25-3.50)		0.30 (-5.00-3.00)		-0.90 (-3.70-3.20)	
ΔWA%									
3rd-	EBV	-9.00 (-17.00--1.00)**	0.037	-5.00 (-12.00-5.50)	0.741	-5.00 (-13.50-5.00)	0.390	1.00 (-7.50-10.00)	0.135
	IBV	-1.00 (-9.75-11.25)		-3.00 (-12.00-3.50)		-8.50 (-15.00--2.75)**		-5.50 (-13.75-2.25)	
4th-	EBV	0.00 (-5.00-3.00)	0.867	0.00 (-4.00-3.00)	0.965	0.00 (-10.50-13.50)	0.657	2.00 (-4.00-12.00)	0.346
	IBV	0.00 (-4.25-3.00)		0.00 (-3.00-5.00)		0.00 (-9.00-3.00)		-1.00 (-4.00-8.00)	

Data are presented as median (Q25 - Q75). * indicates P<0.05; ** indicates P<0.01. WT=wall thickness; WT%=percentage of wall thickness; LA=intraluminal area; WA=wall area; WA%= percentage of wall area.

Table S4 Subgroup analysis: changes in WT% and WA% of contralateral airway

Variables		1-month	3-month	6-month	12-month
Δ WT%					
2nd	Responder	-1.00 (-2.50-2.00)	-1.50 (-8.25-4.25)	-2.00 (-14.75-6.25)	2.00 (-4.25-3.00)
	Non-Responder	1.00 (-3.00-7.00)	0.00 (-5.00-5.00)	-1.00 (-3.00-1.00)	0.00 (-4.50-2.00)
3rd	Responder	0.00 (-4.50-6.00)	-1.00 (-3.25-3.00)	-1.00 (-7.00-3.00)	4.50 (-4.75-8.50)
	Non-Responder	1.00 (-6.00-9.50)	2.00 (-2.75-9.00)	-2.00 (-6.50-7.50)	1.00 (-5.00-8.00)
4th	Responder	0.00 (-4.75-4.00)	0.00 (-3.00-4.00)	-2.50 (-7.00--1.00)**	1.00 (-4.00-5.00)
	Non-Responder	0.00 (-3.00-4.25)	1.00 (-2.00-3.75)	0.00 (-4.00-2.00)	0.00 (-3.50-3.00)
Δ WA%					
2nd	Responder	-3.00 (-5.00-2.50)	-3.50 (-12.50-6.25)	-3.50 (-23.00-9.75)	2.50 (-6.75-5.75)
	Non-Responder	2.00 (-3.00-10.00)	-1.00 (-5.00-7.00)	-1.00 (-5.00-1.00)	-0.50 (-6.50-2.75)
3rd	Responder	0.00 (-6.50-8.50)	-0.50 (-4.25-5.00)	-1.00 (-9.00-4.00)	4.50 (-7.00-13.25)
	Non-Responder	2.00 (-8.50-13.50)	2.00 (-4.00-12.75)	-2.50 (-10.00-7.00)	0.00 (-6.00-11.00)
4th	Responder	0.00 (-6.75-4.75)	-1.00 (-5.00-4.00)	-3.50 (-10.75--1.25)**	2.00 (-6.00-6.00)
	Non-Responder	-0.50 (-4.25-6.00)	1.00 (-2.75-5.00)	-1.00 (-5.00-3.00)	0.00 (-3.50-3.50)

Data are presented as median (Q1, Q3); ** indicate $P < 0.01$; WT%=percentage of wall thickness; WA%= percentage of wall area.